EPA-1088 – The Evaluation of the Effects of Souvenaid on the Quality of Live in Patient with the Diagnosis M.Alzheimer; Real-Life Prospective Clinical Cohort Study

Abstract

Aim:

To evaluate the effect of Souvenaid (a multicomponent nutritional drink for early AD) on cognition, behavioral and psychological symptoms of dementia (BPSD), activity of daily living (ADL) and well-being of M.Alzheimer patients in a real-life prospective clinical setting.

Methods:

Patients (and caregivers) with M.Alzheimer, using Souvenaid, were evaluated after 6 months on cognition, behavior, ADL and wellbeing, based on the KATZ Activity of Daily Living, Mini Mental State Examination (MMSE) and Neuro Psychiatric Inventory (NPI).

Results:

58 Alzheimer patients were included and 43/58 were evaluated after 6-months. 15/58 did not have a follow-up visit yet. 2/58 patients stopped using Souvenaid. 24/43 patients (58,1%) were better or stable on the 4 items mentioned above. 28/43 patients (65%) improved when only evaluating ADL-functions, BPSD and Cognition. Sub-group analyses (1. start Souvenaid and Alzheimer medication together, 2. start Souvenaid < 6 months after start Alzheimer medication, 3. Start Souvenaid > 6 months after start Alzheimer medication); a positive outcome on 4 items was observed in group 1 (57%, 4/7 patients), group 2 (53%, 8/15 patients) and group 3 (57%, 12/21 patients). Another sub-group analyses (MMSE < 20 vs ≥ 20) showed an improvement in 4 items of 28% (2/7 patients) vs 58,8% (20/34 patients).

Conclusion:

Souvenaid is well tolerated in a real-life prospective clinical setting, also in conjunction with standard care Alzheimer medication. Souvenaid may be more beneficial in early stage AD patients and seems to improve quality of life.